In the first part of this review, we will discuss the rise of this drug class to the prominent position in the European Society of Cardiology (ESC) guidelines for HF treatment taking into account, the main clinical trials assessing the potential of SGLT2 inhibitors in patients with high CV risk (Table 1). The gene discussed is SLC5A2; the disease is hydrops fetalis.